Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.,Journal of Antimicrobial Chemotherapy

当前位置： X-MOL 学术 › J. Antimicrob. Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.
Journal of Antimicrobial Chemotherapy ( IF 3.9 ) Pub Date : 2020-08-19 , DOI: 10.1093/jac/dkaa334
Anahita Sadeghi ₁ , Ali Ali Asgari ₁ , Alireza Norouzi ₂ , Zahedin Kheiri ₃ , Amir Anushirvani ₁ , Mahnaz Montazeri ₄ , Hadiseh Hosamirudsai ₅ , Shirin Afhami ₆ , Elham Akbarpour ₁ , Rasoul Aliannejad ₇ , Amir Reza Radmard ₈ , Amir H Davarpanah ₉ , Jacob Levi ₁₀ , Hannah Wentzel ₁₁ , Ambar Qavi ₁₁ , Anna Garratt ₁₂ , Bryony Simmons ₁₃ , Andrew Hill ₁₄ , Shahin Merat ₁

Affiliation

Liver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Golestan Research Center of Gastroenterology and Hepatology, Golestan University of Medical Science, Gorgan, Iran.
Department of Internal Medicine, Baharloo hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of infectious diseases, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Infectious Diseases, Baharloo Hospital, Tehran University of Medical Science, Tehran, Iran.
Department of infectious diseases, Shariati Hospital, Tehran University of Medical Science, Tehran, Iran.
Department of Pulmonary and Critical Care, Shariati Hospital, Thoracic Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Radiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA.
Department of Emergency Medicine, Homerton University Hospital, London, UK.
School of Public Health, Imperial College London, London, UK.
Cardiff and Vale University Health Board, Cardiff, UK.
Department of Infectious Disease, Imperial College London, London, UK.
Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.

Currently no effective antiviral therapy has been found to treat COVID-19. The aim of this trial was to assess if the addition of sofosbuvir and daclatasvir improved clinical outcomes in patients with moderate or severe COVID-19.

中文翻译：

与Sofosbuvir和daclatasvir相比，治疗中度或重度冠状病毒感染（COVID-19）入院患者的治疗标准：一项随机对照试验。

目前，尚未发现有效的抗病毒疗法可治疗COVID-19。该试验的目的是评估在中度或重度COVID-19患者中，添加sofosbuvir和daclatasvir是否能改善临床疗效。

更新日期：2020-10-17

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11